← AI Transformation Suite Business Case · Cost-Benefit Analysis

Cost-Benefit Analysis

Download Word

Executive Summary

Project Catalyst is a $99.0M, 36.5-month investment to build enterprise AI capability at ACME Highland Health across claims & prior authorization, member & provider experience, and underwriting & risk. This analysis models the program over a 10-year horizon at an 8% discount rate. The business case is positive but disciplined: it clears the 8% hurdle with a modest margin, and its return depends on delivering the benefit ramp on schedule. It is presented on conservative assumptions rather than optimistic ones — the intent is a case that holds up under scrutiny, not one that flatters the program.

Total Investment
$99.0M
Over 3 years
Net Present Value
+$2.97M
10-yr, 8% discount
Internal Rate of Return
8.94%
vs. 8% hurdle
Annual Benefit
$27.2M
Full run-rate (Yr 5+)
Payback
~7.6 yrs
simple, from inception
Recommendation: Proceed. The program returns a positive NPV of +$2,968,904 and an IRR of 8.94%, clearing the 8% cost of capital. Simple payback is ~7.6 years from program start (~9.6 years on a discounted basis, within the 10-year window); measured from the start of steady-state operations — once the 3-year build is complete — operational payback is ~4.6 years. Because the margin over the hurdle is modest, approval should be paired with disciplined benefit-realization tracking and the FinOps controls described below.

1 · Approach & Methodology

The analysis compares the fully-loaded program investment against quantified, risk-adjusted operational benefits over a 10-year horizon (Years 1–3 build; Years 4–10 steady-state operation). Key modeling conventions:

2 · Investment (Cost) Model

The $99.0M program investment is drawn against three annual SOW envelopes. Steady-state run cost of $9.5M/year begins once capabilities are in production (Year 4+).

Program YearScopeBuild InvestmentRun-State Cost
Year 1Foundation, CoE, Platform, BRD-01$27,720,000$0
Year 2BRD-02, BRD-03 (peak delivery)$41,580,000$0
Year 3Optimization & sustain, closeout$29,700,000$0
Years 4–10Steady-state operation (per year)$0$9,500,000
Build total$99,000,000$9.5M/yr

Build investment reconciles to the Program Budget and Charter §13.1. Run-state cost reconciles to the ongoing-operations line in the TCO model.

3 · Benefit Model — Full Run-Rate (Year 5+)

Four quantified benefit streams total $27.2M annually at full run-rate, each modeled conservatively from ACME's operating baselines.

Benefit StreamBasis of EstimateAnnual Value
Claims & PA Automation & Labor~800k annual prior-auth requests; AI auto-adjudication of routine cases under clinical oversight reduces manual review labor and cycle time against a ~$30/request baseline cost.$12,800,000
PA & Claims Fraud / Waste DetectionImproved detection of inappropriate or anomalous prior-auth and claims patterns via model scoring.$2,400,000
Member & Provider Experience & DeflectionVirtual-assistant contact deflection plus agent-assist productivity across member and provider service channels.$8,800,000
Underwriting Risk & ProductivityImproved risk selection and underwriter throughput from decision-support scoring (post independent validation).$3,200,000
Total Full Run-Rate Annual Benefit$27,200,000

Benefit Realization Ramp (Years 1–5)

Benefits ramp as capabilities reach production and adoption matures — a deliberately conservative curve given the phased BRD go-lives.

YearPhaseRealizationGross BenefitDrivers
Year 1Build & Pilot0%$0BRD-01 pilot only; no production volume
Year 2BRD-01 ramp + BRD-02/03 pilot25%$6,800,000BRD-01 in production (PA automation ramping); BRD-02/03 in pilot
Year 3Expansion & optimization55%$14,960,000BRD-02 to production; BRD-03 ramping; PA approaching steady-state
Year 4Sustained operations85%$23,120,000All BRDs in steady-state on trailing edge of ramp
Year 5+Full run-rate100%$27,200,000All systems optimized; full benefit capture

4 · 10-Year Cash Flow, NPV, IRR & Payback

Net cash flow combines build investment (Years 1–3), realized gross benefit, and run-state cost (Years 4+), discounted at 8%.

YrInvestmentGross BenefitRun CostNet Cash FlowCumulativePV @ 8%Cum. PV
Y1$27.72M$0$0-$27,720,000-$27.72M-$25,666,667-$25.67M
Y2$41.58M$6.80M$0-$34,780,000-$62.50M-$29,818,244-$55.48M
Y3$29.70M$14.96M$0-$14,740,000-$77.24M-$11,701,087-$67.19M
Y4$0$23.12M$9.50M+$13,620,000-$63.62M+$10,011,107-$57.17M
Y5$0$27.20M$9.50M+$17,700,000-$45.92M+$12,046,323-$45.13M
Y6$0$27.20M$9.50M+$17,700,000-$28.22M+$11,154,002-$33.97M
Y7$0$27.20M$9.50M+$17,700,000-$10.52M+$10,327,780-$23.65M
Y8$0$27.20M$9.50M+$17,700,000+$7.18M+$9,562,759-$14.08M
Y9$0$27.20M$9.50M+$17,700,000+$24.88M+$8,854,407-$5.23M
Y10$0$27.20M$9.50M+$17,700,000+$42.58M+$8,198,525+$2.97M
NPV+$2,968,904
Reading the payback three ways. Because most of the cost is front-loaded and benefits ramp, payback depends on the reference point:

5 · Sensitivity Analysis

NPV sensitivity to a ±20% swing in each key assumption, holding others at base case. Prior-auth volume and baseline cost are the dominant value drivers; delivery-schedule and incident risks are downside-only.

AssumptionBase CaseDownsideBase NPVUpside
PA automation volume (annual requests)800,000-$8.4M+$2.97M+$8.4M
Baseline PA processing cost$30/req-$6.2M+$2.97M+$6.2M
Cloud/compute cost escalation0.8%/yr-$1.8M+$2.97M
Benefit-ramp delay (6 months per BRD)On time-$5.1M+$2.97M
Model incident (pause PA 3 months, Yr 2)No incident-$2.3M+$2.97M
Implication. The case is most exposed to prior-auth volume/cost assumptions and to schedule slippage. A single 6-month ramp delay per BRD (-$5.1M) is enough to push NPV negative — which is why benefit-realization tracking and the FinOps compute controls are treated as conditions of approval, not optional.

6 · Scenario Analysis

ScenarioAssumptions10-Yr NPVPayback (simple)
ConservativeBenefits -20%, one 6-month ramp delay~-$6M> 10 years (Year 11)
BaseModeled assumptions as above+$2.97M~7.6 years
OptimisticBenefits +20%, on-time ramp, lower compute escalation~+$12M~6 years

The spread is deliberately wide: this is a program whose return is earned through execution discipline. The base case is defensible; the conservative case is a genuine downside that governance is designed to prevent.

7 · Indirect & Qualitative Benefits

Not monetized in the model above, but material to the decision:

8 · Risks to Benefit Realization

The benefit case is directly exposed to the program's anticipated risks — each has a mitigation owner on the RAIDD Log:

Bottom line. On conservative assumptions Project Catalyst clears its cost of capital with a positive NPV and an 8.94% IRR, and builds a reusable AI platform, governance capability, and regulatory posture that the numbers above do not fully capture. The recommendation is to proceed, conditioned on disciplined benefit tracking and the compute-cost and adoption controls that the sensitivity analysis shows the case depends on.

Read Alongside

This analysis pairs with the Total Cost of Ownership (10-year run-and-maintain view), the Program Budget (baseline detail), and the Program Charter §2.3 financial summary.